Viramune (nevirapine or NVP) is a non-nucleoside reverse transcriptase inhibitor used to treat HIV/AIDS. It is approved by the U.S. FDA for the treatment of HIV infection in adults and children 15 days and older.
Adult single dose: Take one 200-mg tablet once daily for the first 14 days, then take one 200-mg tablet twice daily.
- The 14-day lead-in period must be strictly followed; it has been demonstrated to reduce the frequency of rash.
- Monitoring during the first 18 weeks of therapy is essential. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of adverse events.
- Resistance can develop quickly. It is very important to take ARVs according to instructions, on schedule, and not to skip or reduce doses.
- Viramune should not be started in women with over 250 CD4 cells or in men with over 400 CD4 cells due to the risk of liver problems.
- Women should not breastfeed while on Viramune.